Archives

Proteomics identifies biomarkers for chemotherapy response prediction in lung cancer

  • December 18, 2023
  • Comments off

Core question: Can we identify predictive protein biomarkers for the selection of patients benefiting from  platinum-based adjuvant chemotherapy (ACT) in non-small cell lung cancer (NSCLC)? Core insight: Our study published Nov 27th in Molecular Oncology presents the discovery of predictive biomarkers that can aid in distinguishing patients with NSCLC likely to derive clinical benefit from […]

Read More

Personalized treatments – Phosphoproteomics research reveals new avenues for developing targeted therapies for patients with pancreatic cancer

  • October 3, 2023
  • Comments off

In our recent study pubished in Cell Reports, PhD student Andrea Valles shows how profile-guided phosphoproteomics can be used to select low dose combination treatment based on three kinase inhibitors. Kinase activity ranking of individual cell lines using our INKA pipeline, provided the rationale for a combination of within pathway and parallel pathway targeting with triple  […]

Read More

Connie Jimenez highlighted in HUPOST as Human of HUPO

  • September 11, 2023
  • Comments off

Connie Jimenez, The Netherlands   What is your current position and location? I am full Professor of Translational OncoProteomics, Principle Investigator of the OncoProteomics Laboratory and Director of the Proteomics Core Resource, all at Amsterdam University Medical Center, in the beautiful city Amsterdam where I was born, in The Netherlands. How did you get started […]

Read More

Published in Science Translational Medicine: Phosphoproteomics identifies hyperactive kinase targets and treatment combinations in colorectal cancer

  • September 6, 2023
  • Comments off

Can mass spectrometry-based phosphoproteomics help understand the (lack of) response to EGFR-blockade and identify predictive markers and new treatment options? We analyzed a unique collection of 29 molecularly characterized colorectal patient-derived xenograft (PDX) tumors, annotated for cetuximab response. Proteomics identified CXADR as promising marker of treatment response, while phosphoproteomics coupled to single sample kinase activity […]

Read More

Folliculin phosphoproteomics study highlighted in ASBMB Today

  • March 14, 2023
  • Comments off

This news article highlights the study of Iris Glycofrydis published in Molecular and Cellular Proteomics last year. It aimed to uncover the functions of the tumor suppressor Foliculin that plays a role in renal cancer (DOI:10.1016/j.mcpro.2022.100263 ). NB On Nov 22, 2022 she defended her thesis including this study in an excellent manner! See page […]

Read More

19 jan. 2023, Thesis defense Carolien van Alphen “Unpacking the phosphoproteome in AML”

  • January 29, 2023
  • Comments off

Photo impression of a great day that started with a seminar entitled “Phosphoproteomics approaches to rationalise anticancer drug responses: towards next generation precision medicine ” by Prof. Pedro Cutillas of the Barts Cancer Institute in London, followed by the thesis defense ceremony. Carolien did a good job defending her thesis. Together copromotor Jacqueline Cloos and […]

Read More

Position open for mass spectrometrist

  • November 24, 2022
  • Comments off

Biomedical Mass Spectrometry/ Proteomics Expert Academic Transfer: Biomedical Mass Spectrometry/ Proteomics Expert Amsterdam UMC: Vacatures – Biomedical Mass Spectrometry/ Proteomics Expert Position We are looking for an accomplished (Senior) Scientist with ample mass spectrometry expertise, to join the OncoProteomics Laboratory at the Amsterdam University Medical Center. Our focus is on innovative proteomics and data analysis […]

Read More

Souvenir IMSC2022 Clinical Proteomics Course

  • September 20, 2022
  • Comments off

Picture Impression of the short course “Clinical Proteomics” at IMSC2022 in Maastricht. A great thanks to all the course contributors Sander Piersma, Irene Bijnsdorp and Tami Geiger.

Read More